Erlotinib Terminated Phase 2 Trials for Recurrent or Refractory Pediatric Ependymoma Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01032070Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma